{
    "elements": [
        {
            "type": "image",
            "sequence_num": 1,
            "data": {
                "url": "15000 Fetal neuroprotection prior to preterm birth 3.0.001.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 2,
            "data": {
                "num_rows": 16,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Title:"
                    },
                    {
                        "text": "FETAL NEUROPROTECTION PRIOR TO PRETERM BIRTH"
                    },
                    {
                        "text": "Document Reference/Register no:"
                    },
                    {
                        "text": "15000"
                    },
                    {
                        "text": "Version Number:"
                    },
                    {
                        "text": "3.0"
                    },
                    {
                        "text": "Document type: (Policy/ Guideline/ SOP/CCP)"
                    },
                    {
                        "text": "Guideline"
                    },
                    {
                        "text": "To be followed by: (Target Staff)"
                    },
                    {
                        "text": "Midwives, Obstetricians, Paediatricians"
                    },
                    {
                        "text": "Ratification Issue Date: (Date document is uploaded onto the intranet)"
                    },
                    {
                        "text": "15 February 2021"
                    },
                    {
                        "text": "Review Date:"
                    },
                    {
                        "text": "14 February 2024"
                    },
                    {
                        "text": "Key word(s) to search for document on intranet:"
                    },
                    {
                        "text": "Fetal Neuroprotection, Preterm"
                    },
                    {
                        "text": "Developed in response to: (National Guidance/Recommendations (i.e. NICE; RCOG)"
                    },
                    {
                        "text": "NICE Preterm Labour and Birth NG25"
                    },
                    {
                        "text": "Contributes to HSC Act 2008 (Regulated Activities) Regulations 2014(Part 3); and CQC Regulations 2009 (Part 4) CQC Fundamental Standards of Quality and Safety:"
                    },
                    {
                        "text": "12"
                    },
                    {
                        "text": "Issuing Division/Directorate:"
                    },
                    {
                        "text": "Women's and Children's"
                    },
                    {
                        "text": "Author/Contact: (Asset Administrator)"
                    },
                    {
                        "text": "Miss Rao"
                    },
                    {
                        "text": "Obstetric Consultant"
                    },
                    {
                        "text": "Hospital Sites: (tick appropriate box(s) to indicate status of policy review i.e. joint/ independent)"
                    },
                    {
                        "text": "\u2610 MSE NHS Foundation Trust \u2610 Basildon Hospital \u2612 Broomfield Hospital \u2610 Southend Hospital \u2610 Other (please state)"
                    },
                    {
                        "text": "Approval Group / Committee(s):"
                    },
                    {
                        "text": "Maternity and Gynaecology Practice Steering Group"
                    },
                    {
                        "text": "28 January 2021"
                    },
                    {
                        "text": "Consultation:"
                    },
                    {
                        "text": "(Refer to page 2)"
                    },
                    {
                        "text": "Professionally Approved by: (Asset Owner)"
                    },
                    {
                        "text": "Miss Thakur"
                    },
                    {
                        "text": "Clinical Director"
                    },
                    {
                        "text": "28 January 2021"
                    },
                    {
                        "text": "Ratification Group(s):"
                    },
                    {
                        "text": "Joint Document Management Group"
                    },
                    {
                        "text": "09 February 2021"
                    },
                    {
                        "text": "Executive and Clinical Directors (Communication of minutes from Joint Document Management Group)"
                    },
                    {
                        "text": "February 2021"
                    },
                    {
                        "text": "Distribution Method:"
                    },
                    {
                        "text": "\u2612 Trust Intranet \u2610 Internet"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "image",
            "sequence_num": 3,
            "data": {
                "url": "15000 Fetal neuroprotection prior to preterm birth 3.0.002.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 4,
            "data": {
                "num_rows": 14,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Consulted With: (Must include Specialist Pharmacists if the document has any reference to medication)"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "Miss Dutta"
                    },
                    {
                        "text": "Obstetrics and Gynaecology Consultant"
                    },
                    {
                        "text": "28 January 2021"
                    },
                    {
                        "text": "Miss Kausar"
                    },
                    {
                        "text": "Obstetrics and Gynaecology Consultant"
                    },
                    {
                        "text": "28 January 2021"
                    },
                    {
                        "text": "Mr Partington"
                    },
                    {
                        "text": "Obstetrics and Gynaecology Consultant"
                    },
                    {
                        "text": "28 January 2021"
                    },
                    {
                        "text": "Miss Sharma"
                    },
                    {
                        "text": "Obstetrics and Gynaecology Consultant"
                    },
                    {
                        "text": "28 January 2021"
                    },
                    {
                        "text": "Miss Joshi"
                    },
                    {
                        "text": "Obstetrics and Gynaecology Consultant"
                    },
                    {
                        "text": "28 January 2021"
                    },
                    {
                        "text": "Mr Spencer"
                    },
                    {
                        "text": "Obstetrics and Gynaecology Consultant"
                    },
                    {
                        "text": "28 January 2021"
                    },
                    {
                        "text": "Mr Gangooly"
                    },
                    {
                        "text": "Obstetrics and Gynaecology Consultant"
                    },
                    {
                        "text": "28 January 2021"
                    },
                    {
                        "text": "Mr Fiadjoe"
                    },
                    {
                        "text": "Obstetrics and Gynaecology Consultant"
                    },
                    {
                        "text": "28 January 2021"
                    },
                    {
                        "text": "Ros Bullen-Bell"
                    },
                    {
                        "text": "Head of Midwifery"
                    },
                    {
                        "text": "28 January 2021"
                    },
                    {
                        "text": "Angela Woolfenden"
                    },
                    {
                        "text": "Lead Midwife for Community Services"
                    },
                    {
                        "text": "28 January 2021"
                    },
                    {
                        "text": "Amanda Dixon"
                    },
                    {
                        "text": "Lead Midwife for Acute Services and Labour Ward Manager"
                    },
                    {
                        "text": "28 January 2021"
                    },
                    {
                        "text": "Bernie O'Sullivan"
                    },
                    {
                        "text": "Senior Midwife DAU"
                    },
                    {
                        "text": "28 January 2021"
                    },
                    {
                        "text": "Claire Fitzgerald"
                    },
                    {
                        "text": "Specialist Pharmacist for Women and Children's Services"
                    },
                    {
                        "text": "28 January 2021"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 5,
            "data": {
                "num_rows": 2,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Post/ Approval Committee/ Group: (Must include Medication Assurance Committee if the document has any reference to medication)"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "Maternity and Gynaecology Practice Steering Group"
                    },
                    {
                        "text": "28 January 2021"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 6,
            "data": {
                "num_rows": 2,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Related Trust Policies (to be read in conjunction with)"
                    },
                    {
                        "text": "(Refer to the main body of the text) 04071 Policy for standard infection prevention precautions MSEPO- 20215 Hand Hygiene 06036 Maternity Record Keeping including Documentation in Handheld Records MSEPO-20239 Clinical record keeping and standards policy 05110 Management of severe pre-eclampsia and eclampsia"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 7,
            "data": {
                "num_rows": 8,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Review History:"
                    },
                    {
                        "text": "Version No:"
                    },
                    {
                        "text": "Authored/Reviewer:"
                    },
                    {
                        "text": "Summary of amendments/ Record documents superseded by:"
                    },
                    {
                        "text": "Issue Date:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Beth Gibson, Anita Rao"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "13 Feb 2015"
                    },
                    {
                        "text": "1.1"
                    },
                    {
                        "text": "Miss Joshi"
                    },
                    {
                        "text": "Clarification to point 4.1, 7.0"
                    },
                    {
                        "text": "May 2016"
                    },
                    {
                        "text": "2.0"
                    },
                    {
                        "text": "Mohammed Elrayes"
                    },
                    {
                        "text": "Clarification to points 3.1,4.1, 5.3, 7.1, 9.0, Appendix A, B and D"
                    },
                    {
                        "text": "12 February 2017"
                    },
                    {
                        "text": "2.1"
                    },
                    {
                        "text": "Louise Middleton"
                    },
                    {
                        "text": "Clarification to the title to remove term magnesium sulphate"
                    },
                    {
                        "text": "04 June 2019"
                    },
                    {
                        "text": "2.2"
                    },
                    {
                        "text": "Maxine Ridley \u2013Snell"
                    },
                    {
                        "text": "Additional Points 5.3.1, 5.3.2, 5.3.3, clarification to points 4.2, 5.2, Appendix B"
                    },
                    {
                        "text": "04 February 2020"
                    },
                    {
                        "text": "3.0"
                    },
                    {
                        "text": "Maxine Ridley\u2013Snell Miss Rao"
                    },
                    {
                        "text": "Full review, update front page. Addition of Magnesium Sulphate sticker to guideline"
                    },
                    {
                        "text": "15 February 2021"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 8,
            "data": {
                "is_heading": 1,
                "text": "Contents"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 9,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": "Purpose ........................................................................................................................ 4"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 10,
            "data": {
                "is_heading": 0,
                "prefix": 2.0,
                "text": "Background .................................................................................................................. 4"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 11,
            "data": {
                "is_heading": 0,
                "prefix": 3.0,
                "text": "Role & Responsibilities within the Trust ........................................................................ 4"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 12,
            "data": {
                "is_heading": 0,
                "prefix": 4.0,
                "text": "Indications for Use ........................................................................................................ 5"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 13,
            "data": {
                "is_heading": 0,
                "prefix": 5.0,
                "text": "Good Practice Points .................................................................................................... 5"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 14,
            "data": {
                "is_heading": 0,
                "prefix": 6.0,
                "text": "Magnesium Sulphate Regimen ..................................................................................... 6"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 15,
            "data": {
                "is_heading": 0,
                "prefix": 7.0,
                "text": "Monitoring ..................................................................................................................... 6"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 16,
            "data": {
                "is_heading": 0,
                "prefix": 8.0,
                "text": "Toxicity ......................................................................................................................... 7"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 17,
            "data": {
                "is_heading": 1,
                "prefix": 17.0,
                "text": "Interactions ................................................................................................................... 8  Fetal and Neonatal Effects ........................................................................................... 8  Training Requirements ................................................................................................. 8  Professional Midwifery Advocates ................................................................................ 8  Infection Prevention ...................................................................................................... 8  Monitoring and Audit ..................................................................................................... 9  Approval and Implementation ....................................................................................... 9  Equality Impact Assessment ......................................................................................... 9  References ................................................................................................................... 9 Appendix A: Considerations for the use of Magnesium Sulphate (MgSO4) ....................... 11 Appendix B: Drug Protocol for Magnesium Sulphate for Fetal neuroprotection ................. 12 Appendix C: Drug Protocol for Calcium Gluconate ............................................................ 13 Appendix D: Management of Patient who has received Magnesium Sulphate ................. 14 Appendix E: Preliminary Equality Analysis ......................................................................... 15"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 18,
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "Purpose"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 19,
            "data": {
                "is_heading": 1,
                "prefix": 1.1,
                "text": "The purpose of this guideline is to provide guidance to clinicians for the use of Magnesium Sulphate (MgSO4) to women at risk of preterm birth in order to prevent cerebral palsy of the infant."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 20,
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "Background"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 21,
            "data": {
                "is_heading": 0,
                "prefix": 2.1,
                "text": "The prevalence of preterm birth is increasing. Preterm birth is the single biggest cause of neonatal mortality and morbidity in the UK. Over 52,000 babies (around 7.3% of live births) in England and Wales in 2012 were born preterm \u2013 that is, before 37+0 weeks of pregnancy. There has been no decline in the preterm birth rate in the UK over the last 10 years."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 22,
            "data": {
                "is_heading": 0,
                "prefix": 2.2,
                "text": "While the survival of infants born preterm has improved, the prevalence of cerebral palsy has risen. The incidence of cerebral palsy decreases significantly with increasing gestational age: 14.6% at 22-27 weeks gestation, 6.2% at 28-31 weeks, 0.7% at 32-36 weeks and 0.1% in term infants. Twenty-five percent of all cases of cerebral palsy are in infants born at less than 34 weeks gestation. In children born preterm the proportion whose cerebral palsy is considered to have a perinatal origin (49%) is greater than in those born at term (35%). Strategies to reduce cerebral palsy in these infants should be considered and implemented in order to reduce the effects of this disabling condition on individuals, families, health care and society."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 23,
            "data": {
                "is_heading": 1,
                "prefix": 2.3,
                "text": "Antenatal MGSO4 therapy given to women at risk of preterm labour significantly reduces the risk of their infant developing cerebral palsy (risk ratio (RR) 0.68: 95% confidence interval (CI) 0.54 - 0.87; five trials, 6145 infants) and also significantly reduces the rate of gross motor dysfunction (RR 0.61; 95% CI 0.44-0.85)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 24,
            "data": {
                "is_heading": 0,
                "prefix": 56.0,
                "text": "There is continuing debate on the gestational age at which Magnesium Sulphate has the greatest benefit. The number needed to treat (NNT) to prevent cerebral palsy or severe motor dysfunction increases significantly with increasing gestational age. The number needed to treat at less than 28 weeks gestation is 29, at 30 weeks NNT is  and less than 32-34 weeks the NNT is"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 25,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Roles and responsibilities"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 26,
            "data": {
                "is_heading": 0,
                "prefix": 3.1,
                "text": "The Specialist Nurse for Guidelines and Audit is responsible for ensuring clinical policies, guidelines and SOPs are evidence-based and developed in line with national guidelines and following appropriate consultation."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 27,
            "data": {
                "is_heading": 0,
                "prefix": 3.2,
                "text": "The clinical director is responsible for the implementation of this guideline within the directorate."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 28,
            "data": {
                "is_heading": 0,
                "prefix": 3.3,
                "text": "The Head of Midwifery, maternity matrons and maternity managers are responsible for ensuring maternity staff are aware of the guideline and implement it."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 29,
            "data": {
                "is_heading": 0,
                "prefix": 3.4,
                "text": "The Obstetric Clinical Lead Consultant and Labour Ward Lead Consultant are responsible for ensuring the implementation of this guideline within the clinical setting."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 30,
            "data": {
                "is_heading": 0,
                "prefix": 3.5,
                "text": "All maternity staff are responsible for ensuring they are familiar with this guideline in relation to their practice and have the appropriate skills to implement this guideline."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 31,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "Indications for use"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 32,
            "data": {
                "is_heading": 1,
                "prefix": 4.1,
                "text": "Magnesium sulphate for neuroprotection of the fetus, newborn and child should be offered to women between 24 weeks and 0 days and 33 weeks and 6 days gestation (or less where a viable outcome is anticipated) who are in established preterm labour or"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 33,
            "data": {
                "is_heading": 0,
                "text": "having a planned preterm birth within 24 hours."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 34,
            "data": {
                "is_heading": 0,
                "text": "Regardless of plurality (number of babies in utero);"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 35,
            "data": {
                "is_heading": 0,
                "text": "Regardless of parity;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 36,
            "data": {
                "is_heading": 0,
                "text": "Regardless of anticipated mode of delivery;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 37,
            "data": {
                "is_heading": 0,
                "text": "Whether or not antenatal corticosteroids have been given;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 38,
            "data": {
                "is_heading": 0,
                "text": "If at 23 weeks gestation the parents wish for the baby to be resuscitated and given intensive care the mother must be given magnesium. If parents have decided against active resuscitation it would not be appropriate to give magnesium."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 39,
            "data": {
                "is_heading": 0,
                "prefix": 4.2,
                "text": "The final decision on MgSO4 administration must be made by either the Consultant Obstetrician or the Obstetric Registrar (having discussed with an Obstetric Consultant)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 40,
            "data": {
                "is_heading": 0,
                "prefix": 4.3,
                "text": "When early preterm birth is planned commence magnesium sulphate as close to four hours before birth as possible."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 41,
            "data": {
                "is_heading": 1,
                "prefix": 24.0,
                "text": "Preterm birth is a retrospective diagnosis. By highlighting those women at particular risk we attempt to define unplanned expected preterm birth within  hours:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 42,
            "data": {
                "is_heading": 0,
                "text": "Women with cervical dilatation \u22644cm on speculum/vaginal examination with regular contractions;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 43,
            "data": {
                "is_heading": 0,
                "text": "Women with intact membranes and positive Partosure/Actim Partus/Fetal fibronectin with symptoms of threatened preterm labour;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 44,
            "data": {
                "is_heading": 0,
                "text": "Women with preterm rupture of membranes who are contracting."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 45,
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "Good practice points"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 46,
            "data": {
                "is_heading": 1,
                "prefix": 5.1,
                "text": "Timing"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 47,
            "data": {
                "is_heading": 0,
                "text": "If delivery before 34 weeks is anticipated to occur sooner than 4 hours, there"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 48,
            "data": {
                "is_heading": 0,
                "text": "continues to be some advantage from administration of Magnesium therefore it"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 49,
            "data": {
                "is_heading": 0,
                "text": "should be given."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 50,
            "data": {
                "is_heading": 1,
                "prefix": 5.2,
                "text": "Urgent delivery"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 51,
            "data": {
                "is_heading": 0,
                "text": "If urgent delivery is required for maternal/fetal compromise (e.g. fetal distress/antepartum haemorrhage) then delivery must not be delayed to administer Magnesium Sulphate. Consideration must be given to administering the loading dose during the preparation for delivery."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 52,
            "data": {
                "is_heading": 1,
                "prefix": 5.3,
                "text": "Repeat doses"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 53,
            "data": {
                "is_heading": 0,
                "text": "5.3.1 If Magnesium Sulphate has been given and preterm birth does not occur but at a later time appears imminent, a repeat dose of Magnesium Sulphate may be considered."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 54,
            "data": {
                "is_heading": 0,
                "text": "5.3.2 With each new episode of labour the full regime of Magnesium Sulphate must be recommenced."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 55,
            "data": {
                "is_heading": 0,
                "prefix": 24.0,
                "text": "5.3.3 The advice is not to exceed 28g over  hours (4g + (1g x 24)). Magnesium Sulphate is excreted from the kidneys so does not remain in maternal circulation of significant periods; thus it is only considered to be \u2018neuroprotective' for the duration it is being administered and shortly after this."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 56,
            "data": {
                "is_heading": 1,
                "prefix": 5.4,
                "text": "Place of administration"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 57,
            "data": {
                "is_heading": 0,
                "text": "MgSO4 must be administered on Labour Ward where there are appropriate staff"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 58,
            "data": {
                "is_heading": 0,
                "text": "and resources for adequate maternal and fetal monitoring."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 59,
            "data": {
                "is_heading": 1,
                "prefix": 5.5,
                "text": "In utero transfer"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 60,
            "data": {
                "is_heading": 0,
                "text": "IV Magnesium sulphate must only be administered where maternal ventilatory and respiratory support is immediately available. Therefore Magnesium sulphate must"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 61,
            "data": {
                "is_heading": 0,
                "text": "be stopped during the transfer."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 62,
            "data": {
                "is_heading": 1,
                "prefix": 6.0,
                "text": "Magnesium Sulphate regimen"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 63,
            "data": {
                "is_heading": 0,
                "text": "(Refer to Appendix A)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 64,
            "data": {
                "is_heading": 1,
                "prefix": 6.1,
                "text": "Loading dose:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 65,
            "data": {
                "is_heading": 1,
                "prefix": 20.0,
                "text": "Give 4g MgSO4 intravenously over  minutes via an infusion pump."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 66,
            "data": {
                "is_heading": 1,
                "prefix": 6.2,
                "text": "Maintenance dose:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 67,
            "data": {
                "is_heading": 0,
                "text": "Continue to infuse MgSO4 IV at 1gram/hour"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 68,
            "data": {
                "is_heading": 0,
                "text": "Continue regimen until birth or 24 hours, whichever comes first"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 69,
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "Monitoring"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 70,
            "data": {
                "is_heading": 1,
                "prefix": 7.1,
                "text": "Maternal monitoring: Maternal Monitoring for signs of toxicity"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 71,
            "data": {
                "is_heading": 0,
                "text": "Hourly urine output"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 72,
            "data": {
                "is_heading": 0,
                "text": "Hourly respiratory rate"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 73,
            "data": {
                "is_heading": 0,
                "text": "2 hourly blood pressure"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 74,
            "data": {
                "is_heading": 1,
                "text": "Reflexes and Consciousness (Alert; Verbal, Pain, Unresponsive Score) assessed 4-6 hourly"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 75,
            "data": {
                "is_heading": 1,
                "prefix": 7.2,
                "text": "Fetal monitoring"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 76,
            "data": {
                "is_heading": 0,
                "text": "7.2.1 If labour has been diagnosed with continuous cardiotococgraph (CTG)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 77,
            "data": {
                "is_heading": 0,
                "text": "7.2.2 In the absence of complications, fetal monitoring should be performed 8 hourly."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 78,
            "data": {
                "is_heading": 0,
                "prefix": 28.0,
                "text": "From  weeks with CTG"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 79,
            "data": {
                "is_heading": 0,
                "text": "In the absence of complications fetal monitoring must be undertaken 8 hourly"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 80,
            "data": {
                "is_heading": 0,
                "text": "27+6 and below with intermittent auscultation."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 81,
            "data": {
                "is_heading": 1,
                "prefix": 8.0,
                "text": "Toxicity"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 82,
            "data": {
                "is_heading": 0,
                "prefix": 8.1,
                "text": "Toxicity is unlikely with the described protocols, serum Magnesium levels do not require monitoring unless the woman has renal compromise."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 83,
            "data": {
                "is_heading": 0,
                "prefix": 8.2,
                "text": "Toxicity levels correlate with serum magnesium concentrations:"
            }
        },
        {
            "type": "table",
            "sequence_num": 84,
            "data": {
                "num_rows": 5,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": ""
                    },
                    {
                        "text": "Magnesium Level (mmol/l)"
                    },
                    {
                        "text": "Therapeutic range (for PET/unknown for neuroprotection"
                    },
                    {
                        "text": "2-4"
                    },
                    {
                        "text": "Loss of tendon reflexes, weakness, nausea, feeling of warmth, flushing, somnolence, double vision, slurred speech."
                    },
                    {
                        "text": "5"
                    },
                    {
                        "text": "Muscle paralysis, respiratory arrest"
                    },
                    {
                        "text": "6-7.5"
                    },
                    {
                        "text": "Cardiac arrest"
                    },
                    {
                        "text": ">12"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 85,
            "data": {
                "is_heading": 0,
                "text": "Suggested action if toxicity is present:"
            }
        },
        {
            "type": "table",
            "sequence_num": 86,
            "data": {
                "num_rows": 2,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Loss of Patellar reflex"
                    },
                    {
                        "text": "Stop maintenance infusion Check Magnesium level Withhold further Magnesium until reflexes return or serum levels known"
                    },
                    {
                        "text": "Oxygen Saturation persistently <92%"
                    },
                    {
                        "text": "Commence facial oxygen Check patellar reflexes, inform Obstetricians and Anaesthetists If patellar reflexes present then exclude"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 87,
            "data": {
                "num_rows": 1,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": ""
                    },
                    {
                        "text": "other causes If patellar reflexes absent then act as above"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 88,
            "data": {
                "is_heading": 1,
                "prefix": 9.0,
                "text": "Interactions"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 89,
            "data": {
                "is_heading": 0,
                "prefix": 9.1,
                "text": "Theoretically the neuromuscular blockade effect of Magnesium could be exacerbated by concurrent use of Nifedipine. This is seldom reported in clinical practice. If the mother becomes hypotensive, use of both drugs must be reviewed by the on-call Obstetrician."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 90,
            "data": {
                "is_heading": 1,
                "prefix": 10.0,
                "text": "Fetal and neonatal effects"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 91,
            "data": {
                "is_heading": 0,
                "prefix": 10.1,
                "text": "The responsible midwife at birth should inform the Paediatric team that the mother has been receiving MgSo4. An alert sticker for Magnesium Sulphate for Neuro Protection must be placed in the Maternity and/or Neonatal notes."
            }
        },
        {
            "type": "image",
            "sequence_num": 92,
            "data": {
                "url": "15000 Fetal neuroprotection prior to preterm birth 3.0.003.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 93,
            "data": {
                "is_heading": 0,
                "prefix": 24.0,
                "text": "Neonatal hypermagnesaemia may produce hyporeflexia leading to poor sucking and rarely respiratory depression. This effect lasts for up to  hours following birth. The neonatal team must be aware the mother has had Magnesium Sulphate."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 94,
            "data": {
                "is_heading": 1,
                "prefix": 11.0,
                "text": "Staffing and training"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 95,
            "data": {
                "is_heading": 0,
                "prefix": 11.1,
                "text": "All midwifery and obstetric staff must attend yearly mandatory training which includes skill and drills training."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 96,
            "data": {
                "is_heading": 0,
                "prefix": 11.2,
                "text": "All midwifery and obstetric staff are to ensure that their knowledge and skills are up-to-date in order to complete their portfolio for appraisal."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 97,
            "data": {
                "is_heading": 1,
                "prefix": 11.3,
                "text": "Guideline Management"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 98,
            "data": {
                "is_heading": 0,
                "text": "11.3.1 As an integral part of the knowledge, skills framework, staff are appraised annually to ensure competency in computer skills and the ability to access the current approved guidelines via the Trust's intranet site."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 99,
            "data": {
                "is_heading": 1,
                "prefix": 12.0,
                "text": "Professional midwifery advocates"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 100,
            "data": {
                "is_heading": 0,
                "prefix": 12.1,
                "text": "Professional Midwifery Advocates provide a mechanism of support and guidance to women and midwives. Professional Midwifery Advocates are experienced practising midwives who have undertaken further education in order to supervise midwifery services and to advise and support midwives and women in their care choices."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 101,
            "data": {
                "is_heading": 1,
                "prefix": 13.0,
                "text": "Infection prevention"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 102,
            "data": {
                "is_heading": 0,
                "prefix": 13.1,
                "text": "All staff must follow Trust guidelines on infection prevention by ensuring that they effectively \u2018decontaminate their hands' before and after each procedure."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 103,
            "data": {
                "is_heading": 0,
                "prefix": 13.2,
                "text": "All staff must ensure that they follow Trust guidelines on infection prevention. All invasive devices must be inserted and cared for using High Impact Intervention guidelines to reduce the risk of infection and deliver safe care. This care should be recorded in the Saving Lives High Impact Intervention Monitoring Tool Paperwork (Medical Devices)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 104,
            "data": {
                "is_heading": 1,
                "prefix": 14.0,
                "text": "Monitoring and audit"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 105,
            "data": {
                "is_heading": 0,
                "prefix": 14.1,
                "text": "Audit of compliance with this guideline will be considered on an annual audit basis in accordance with the Clinical Audit Strategy and Policy (register number 08076), the Corporate Clinical Audit and Quality Improvement Project Plan and the Maternity annual audit work plan; to encompass national and local audit and clinical governance identifying key harm themes. The Women's and Children's Clinical Audit Group will identify a lead for the audit."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 106,
            "data": {
                "is_heading": 0,
                "prefix": 14.2,
                "text": "The findings of the audit will be reported to and approved by the Multi-disciplinary Risk Management Group (MRMG) and an action plan with named leads and timescales will be developed to address any identified deficiencies. Performance against the action plan will be monitored by this group at subsequent meetings."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 107,
            "data": {
                "is_heading": 0,
                "prefix": 14.3,
                "text": "The audit report will be reported to the monthly Directorate Governance Meeting (DGM) and significant concerns relating to compliance will be entered on the local Risk Assurance Framework."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 108,
            "data": {
                "is_heading": 0,
                "prefix": 14.4,
                "text": "Key findings and learning points from the audit will be submitted to the Patient Safety Group within the integrated learning report."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 109,
            "data": {
                "is_heading": 0,
                "prefix": 14.5,
                "text": "Key findings and learning points will be disseminated to relevant staff."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 110,
            "data": {
                "is_heading": 1,
                "prefix": 15.0,
                "text": "Approval and implementation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 111,
            "data": {
                "is_heading": 0,
                "prefix": 15.1,
                "text": "All policies, procedures and guidelines will be approved locally by the Maternity and Gynaecology Practice Steering Group prior to submission to the Controlled Document team for ratification by the Joint Document Management Group."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 112,
            "data": {
                "is_heading": 0,
                "prefix": 15.2,
                "text": "It is the Guidelines and Audit Nurse's and author's responsibility to inform the Maternity and Gynaecology Practice Steering Group and appropriate Maternity Services' staff of the approved policy documents when they are uploaded to the Trust's Intranets."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 113,
            "data": {
                "is_heading": 1,
                "prefix": 16.0,
                "text": "Equality impact assessment"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 114,
            "data": {
                "is_heading": 1,
                "prefix": 16.1,
                "text": "This Trust is committed to the provision of a service that is fair, accessible and meets the needs of all individuals."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 115,
            "data": {
                "is_heading": 1,
                "prefix": 17.0,
                "text": "References"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 116,
            "data": {
                "is_heading": 0,
                "text": "RCOG Scientific Impact Paper No 29 August 2011: Magnesium Sulphate to Prevent Cerebral Palsy Following Preterm Birth. Available at: www.rcog.org.uk/en/guidelines-research-services/guidelines/sip29"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 117,
            "data": {
                "is_heading": 0,
                "text": "Doyle LW, Crowther CA, Middleton P, Marret S, Rouse D. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Sys Rev 2009. Available at: https://doi.org/10.1002/14651858.CD004461.pub3"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 118,
            "data": {
                "is_heading": 0,
                "text": "Constantine MM, Weiner SJ, Shriver EK (NICHD). Maternal-Fetal Medicine Units Network (MFMU). Effects of antenatal exposure to magnesium sulphate on neuroprotection and mortality in preterm infants: a meta-analysis. Obstetrics & Gynecology 2009: 114(2):354-64."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 119,
            "data": {
                "is_heading": 0,
                "text": "The Antenatal Magnesium Sulphate for Neuroprotection Guideline Development Panel. Antenatal Magnesium Sulphate Prior to Preterm Birth for Neuroprotection of the Fetus, Infant and Child: National Clinical Practice Guidelines 2010 Feb. Available at: www.adelaide.edu.au/arch/antenatalMagnesium_SulphateGuidelines.pdf"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 120,
            "data": {
                "is_heading": 0,
                "text": "National Institute for Health and Care Excellence (2015) Preterm labour and birth (NG25) London:NICE. Available at:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 121,
            "data": {
                "is_heading": 0,
                "text": "https://www.nice.org.uk/guidance/ng25"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 122,
            "data": {
                "is_heading": 0,
                "text": "Rouse D et al (2008) A Randomized, Controlled Trial of Magnesium Sulfate for the Prevention of Cerebral Palsy. New England Journal of Medicine, 359(9), pp.895- 905"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 123,
            "data": {
                "is_heading": 0,
                "text": "Luyt K, Treloar E, Remmers A, Evans D, Wooley R (2018) PReCePT Prevention of Cerebral Palsy in PreTerm Labour, Magnesium Sulphate for Neuroprotection- Quality Improvement Toolkit. s.l. : West of England AHSN Available at: www.ahsnnetwork.com/about-academic-health-science-networks/national- programmes-priorities/precept/precept-resources"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 124,
            "data": {
                "is_heading": 1,
                "text": "Luyt, K. (2018) PReCePT FAQ. [email] cited in UCL Partners (2019) PReCePT FAQ for Midwife Champions. In PReCePT Update. [email]"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 125,
            "data": {
                "is_heading": 1,
                "text": "UCL Partners (2019) PReCePT FAQ for Midwife Champions. In PReCePT Update. [email]"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 126,
            "data": {
                "is_heading": 1,
                "text": "Appendix A: Considerations for the use of Magnesium Sulphate (MgSO )"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 127,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 128,
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "General considerations before commencing administration of magnesium sulphate (MgS04)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 129,
            "data": {
                "is_heading": 0,
                "prefix": 1.1,
                "text": "MgS04 overdose causes loss of deep tendon reflexes, followed by respiratory depression and ultimately respiratory arrest. Calcium gluconate (treatment for respiratory depression due to overdose of MgSO )"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 130,
            "data": {
                "is_heading": 0,
                "prefix": 4.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 131,
            "data": {
                "is_heading": 0,
                "text": "(Refer to Appendix C)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 132,
            "data": {
                "is_heading": 0,
                "prefix": 1.2,
                "text": "Overdose is more likely if there is poor renal function. Blood levels must be monitored."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 133,
            "data": {
                "is_heading": 0,
                "prefix": 1.3,
                "text": "Therapy can be monitored clinically"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 134,
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "Clinical Monitoring"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 135,
            "data": {
                "is_heading": 0,
                "text": "As mentioned in paragraph 7.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 136,
            "data": {
                "is_heading": 0,
                "prefix": 2.1,
                "text": "The drug must be given slowly; the patient will first feel warm."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 137,
            "data": {
                "is_heading": 0,
                "prefix": 2.2,
                "text": "If given too fast, the patient will be will be nauseated and vomit. If this happens stop the infusion until the symptoms subside and the patient is no longer nauseated."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 138,
            "data": {
                "is_heading": 1,
                "text": "Appendix B: Drug protocol for Magnesium Sulphate (MgSo ) for"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 139,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "fetal neuroprotection"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 140,
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "An IV bolus dose of MgS04 4g is given over 20 minutes, followed by maintenance infusion of 1g per hour for 24 hours or until delivery, whichever is first."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 141,
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "Preparation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 142,
            "data": {
                "is_heading": 0,
                "prefix": 30.0,
                "text": "Reconstitute 2 ampoules of magnesium sulphate (each containing 5g of magnesium sulphate in  ml) with  ml of sodium chloride 0.9% in a luer lock 50 ml syringe."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 143,
            "data": {
                "is_heading": 0,
                "text": "This makes a solution of 50mls of 20% magnesium sulphate i.e. 5mls contains 1g magnesium sulphate."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 144,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Loading Dose"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 145,
            "data": {
                "is_heading": 0,
                "prefix": 3.1,
                "text": "Give 4g of the 20% magnesium sulphate solution over 20 minutes."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 146,
            "data": {
                "is_heading": 0,
                "prefix": 20.0,
                "text": "4g MgSO4=  ml over  minutes"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 147,
            "data": {
                "is_heading": 0,
                "prefix": 3.2,
                "text": "Use a Braun Syringe Driver following the manufacturer's instructions for loading the Syringe."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 148,
            "data": {
                "is_heading": 0,
                "prefix": 3.3,
                "text": "Set rate to 60mls per hour"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 149,
            "data": {
                "is_heading": 0,
                "prefix": 20.0,
                "text": "Set the Volume to Be Infused (VTBI) to  mls (20mls = 4gms)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 150,
            "data": {
                "is_heading": 0,
                "prefix": 20.0,
                "text": "Set the time to  minutes (should automatically display this)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 151,
            "data": {
                "is_heading": 0,
                "prefix": 20.0,
                "text": "The syringe driver should alarm and stop after  minutes."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 152,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "Maintenance Dose"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 153,
            "data": {
                "is_heading": 0,
                "prefix": 4.1,
                "text": "1g magnesium sulphate (5mls) per hour."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 154,
            "data": {
                "is_heading": 0,
                "prefix": 4.2,
                "text": "Set rate to 5mls per hour"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 155,
            "data": {
                "is_heading": 0,
                "text": "VTBI will be either 30ml (if continuing from loading dose) or 50ml if on the second or third syringe change."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 156,
            "data": {
                "is_heading": 0,
                "text": "Time remaining should be calculated to six hours (for continuation from first syringe) or ten hours (for a full syringe)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 157,
            "data": {
                "is_heading": 0,
                "text": "Nb: syringe will need changing twice in 24hr period."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 158,
            "data": {
                "is_heading": 0,
                "prefix": 14.0,
                "text": "It can be continued at this rate unless the knee jerks are abolished, urine output falls below 50ml in 2 hours or if the respiratory rate falls below  / minute. Magnesium administration must be stopped if oliguria persists."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 159,
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "Optional Regime for Administration of IV Magnesium Sulphate for Loading Dose (not involving Luer lock procedure)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 160,
            "data": {
                "is_heading": 0,
                "prefix": 5.1,
                "text": "The decision for this option should be undertaken by the obstetric registrar or obstetric consultant in the absence of Syringe pump driver"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 161,
            "data": {
                "is_heading": 0,
                "text": "Procedure:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 162,
            "data": {
                "is_heading": 0,
                "text": "1 ampoule of magnesium sulphate (containing 5g of magnesium sulphate in 10 ml)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 163,
            "data": {
                "is_heading": 0,
                "prefix": 20.0,
                "text": "Into a  ml syringe, draw 8ml of magnesium sulphate (discard the remaining 2ml)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 164,
            "data": {
                "is_heading": 0,
                "text": "Add 12ml of normal saline to the 8ml of magnesium sulphate"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 165,
            "data": {
                "is_heading": 0,
                "text": "This constitutes 20ml of 20% of magnesium sulphate"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 166,
            "data": {
                "is_heading": 0,
                "text": "This can be administered intravenously over 5 minutes"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 167,
            "data": {
                "is_heading": 1,
                "text": "Appendix C: Drug protocol for Calcium Gluconate"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 168,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": "Treatment for respiratory depression due to overdose of MgSO"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 169,
            "data": {
                "is_heading": 0,
                "prefix": 4.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 170,
            "data": {
                "is_heading": 0,
                "prefix": 1.1,
                "text": "Significant respiratory depression should be treated with calcium gluconate, 1g IV should be given slowly over ten minutes (10 ml 10% solution)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 171,
            "data": {
                "is_heading": 0,
                "prefix": 1.2,
                "text": "Calcium Gluconate is to be given by a Registrar or Consultant (or an SHO having discussed with the above)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 172,
            "data": {
                "is_heading": 1,
                "text": "CALCIUM GLUCONATE IS KEPT IN THE LABOUR WARD MAGNESIUM SULPHATE TREATMENT BOX."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 173,
            "data": {
                "is_heading": 1,
                "text": "Appendix D: Management of patient who has received MgS04 flowchart"
            }
        },
        {
            "type": "image",
            "sequence_num": 174,
            "data": {
                "url": "15000 Fetal neuroprotection prior to preterm birth 3.0.004.jpeg"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 175,
            "data": {
                "is_heading": 0,
                "text": "Fetal neuroprotection prior to preterm birth / 15000 / 3.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 176,
            "data": {
                "is_heading": 1,
                "prefix": 17.0,
                "text": "Page  of"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 177,
            "data": {
                "is_heading": 0,
                "text": "Fetal neuroprotection prior to preterm birth / 15000 / 3.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 178,
            "data": {
                "is_heading": 1,
                "text": "Appendix E: Preliminary equality analysis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 179,
            "data": {
                "is_heading": 1,
                "text": "This assessment relates to: Fetal neuroprotection prior to preterm birth / 15000 (Please tick all that apply)"
            }
        },
        {
            "type": "table",
            "sequence_num": 180,
            "data": {
                "num_rows": 3,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "\u2610 A change in a service to patients"
                    },
                    {
                        "text": "\u2612 A change to an existing document"
                    },
                    {
                        "text": "\u2610 A change to the way staff work"
                    },
                    {
                        "text": "\u2610 A new document"
                    },
                    {
                        "text": "\u2610 Something else (please give details)"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 181,
            "data": {
                "num_rows": 7,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Questions"
                    },
                    {
                        "text": "Answers"
                    },
                    {
                        "text": "1."
                    },
                    {
                        "text": "What are you proposing to change?"
                    },
                    {
                        "text": "Full review: NICE Preterm Labour and Birth NG25. Update front page. Addition of Magnesium Sulphate sticker to guideline"
                    },
                    {
                        "text": "2."
                    },
                    {
                        "text": "Why are you making this change? (What will the change achieve?)"
                    },
                    {
                        "text": "3 yearly review"
                    },
                    {
                        "text": "3."
                    },
                    {
                        "text": "Who benefits from this change and how?"
                    },
                    {
                        "text": "Patients and clinicians"
                    },
                    {
                        "text": "4."
                    },
                    {
                        "text": "Is anyone likely to suffer any negative impact as a result of this change? If no, please record reasons here and sign and date this assessment. If yes, please complete a full EIA."
                    },
                    {
                        "text": "No"
                    },
                    {
                        "text": "5."
                    },
                    {
                        "text": "a) Will you be undertaking any consultation as part of this change?"
                    },
                    {
                        "text": "Yes"
                    },
                    {
                        "text": "b) If so, with whom?"
                    },
                    {
                        "text": "Refer to pages 1 and 2"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 182,
            "data": {
                "num_rows": 2,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Preliminary analysis completed by:"
                    },
                    {
                        "text": "Name"
                    },
                    {
                        "text": "Miss Rao"
                    },
                    {
                        "text": "Job Title"
                    },
                    {
                        "text": "Obstetrics Consultant"
                    },
                    {
                        "text": "02 January 2020"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 183,
            "data": {
                "is_heading": 1,
                "prefix": 16.0,
                "text": "Page  of"
            }
        }
    ]
}